Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

Invokana Efficacy

Blood drop

Prescribing Information

Great Britain Northern Ireland

Glycaemic Efficacy

Invokana eliminates more blood glucose every day than any other SGLT2i1-5

This is not a head-to-head study; results from phase 1 studies of urinary glucose excretion in patients with type 2 diabetes.1-5

Average Urinary Glucose Excreation

Invokana gets more patients to HbA1c target than any other SGLT2i as add-on to metformin

In patients tolerating Invokana 100 mg who have an eGFR ≥60 mL/min/1.73 m2 and need tighter glycaemic control, the dose can be increased to 300 mg.1

 

This is not a head-to-head study; figures are taken from respective SmPCs.1-4

Clinical Effectiveness of SGLT2 Inhibitors

58% of patients given Invokana 300 mg in addition to metformin achieve the 7% HbA1c target1

Invokana is more effective at reducing HbA1c and weight than some other oral T2DM treatments

Head to head studies are not available for all drug combinations; network meta-analyses (NMA) allow indirect treatment comparisons to be made. This analysis excluded GLP-1 RAs.

 

Methodology: In an independent NMA using a frequentist model, pairwise random-effects were performed to estimate study variance. The aim of this NMA, which reviewed 38 trials involving 23,997 patients, was to assess the comparative safety and efficacy of SGLT2 inhibitors in treating hyperglycaemia in adults with T2DM. Data was not available for ertugliflozin at the time of analysis.6

Reduction in HbA1c

Abbreviations

DPP4 inhibitors: Dipeptidyl Peptidase-4 inhibitors; eGFR: estimated Glomerular Filtration Rate; GLP-1 RAs: Glucagon-like peptide-1 receptor agonists; HbA1c: Haemoglobin A1c; NMA: Network Meta-Analyses; SmPC: Summary of Product Characteristics; SGLT2i: Sodium-Glucose Co-transporter 2 inhibitor; T2DM: Type 2 Diabetes Mellitus.

References

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.